+
Site Tour
IMPLANTABLE
CARDIOVERTER
DEFIBRILLATORS

Designed to continuously monitor patients’ heart rhythm
and detect irregular heartbeats, implantable cardioverter 
defibrillators (ICDs) deliver electrical signals and controlled shocks
in order to restore a normal heart rhythm when necessary.

GALLANT™ ICD SOLUTIONS

Gallant™ single and dual chamber ICDs feature a 40 Joules (J) maximum shock, Bluetooth® connectivity, and improved algorithms to achieve fast and effective therapy optimization for your patients.1,2

Precision Shock Technology

Timing is everything when shocking a patient out of ventricular fibrillation (VF). Precision Shock Technology (PST) delivers the right energy within the right time for greater first-shock success.3-11 Any energy outside this response window is wasted.

LEARN MORE ABOUT PST:

GALLANT™ ICD

RIGHT ENERGY + RIGHT TIME

=

GREATER FIRST-SHOCK SUCCESS3

Powerful therapy assurance

Gallant™ ICD solutions harness smartphone connectivity with long-lasting therapy and features you can intuitively program to meet your patients’ changing needs.

  • Reduce inappropriate therapy with features proven to increase detection capabilities and safety margins12,13
  • Encourage greater patient engagement with app-based remote monitoring
  • Deliver powerful, lasting therapy with a small, contoured design that is 1.5 Tesla (T) and 3T Magnetic Resonance (MR) Conditional*

1.5T AND 3T MAGNETIC RESONANCE IMAGING (MRI)-READY SOLUTIONS*

*For additional information about specific MR Conditional devices and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the Abbott MRI-Ready Systems Manual.
 

ABBOTT MRI-READY SYSTEMS MANUAL

Smartphone connectivity

GREATER ENGAGEMENT

Gallant™ ICD solutions offer smartphone connectivity to encourage greater patient engagement.

97% OF PATIENTS WERE COMPLIANT
using Abbott app-based remote monitoring14

ENABLES EARLIER INTERVENTION
by communicating clinically relevant events sooner

PAIRS WITH OUR SECURE myMERLINPULSE™ APP
to streamline communications with your patients, potentially reducing clinic burden and simplifying workflow

MAY SAVE YOU AND YOUR CLINIC TIME
by reducing unnecessary calls to the clinic


PATIENTS CAN USE THE myMERLINPULSE™ APP TO:

CHECK CONNECTIVITY STATUS
to ensure their device is being properly monitored

ACCESS DEVICE STATUS
to check battery status and device model

FIND SUPPORT RESOURCES
such as clinic information, technical support numbers and frequently asked questions (FAQs) site

SEND DATA MANUALLY
as instructed by a clinician

VIEW HISTORY
of scheduled data transmissions, connection issues and patient notifications


SECURED DATA AND INFORMATION

You don’t have to worry about the safety of patient information with Abbott. The myMerlinPulse™ app transmits device status and information to the Merlin.net™ Patient Care Network through a secure, encrypted connection.

Advanced security measures include:

  • Encryption when data is at rest and in motion
  • Code signed and authenticated in the device, the patient app and the programmer
  • Two-way authentication of credentials, for device and user
Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

TV

References
  1. Thibault B, Waddingham P, Badie N, et al. Acute Electrical Synchronization Achieved With Dynamic Atrioventricular Delays During Biventricular and Left Ventricular MultiPoint Pacing. CJC Open. 2024;7(2):166-175. doi: 10.1016/j.cjco.2024.11.003. 
  2. Calò L, De Ruvo E, Kolb C, et al. Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses. Europace. 2024;26(11):euae259. doi: 10.1093/europace/euae259. Erratum in: Europace. 2025;27(2):euaf022. doi: 10.1093/europace/euaf022. 
  3. Katcher M, Davis K, Badie N, et al. Improved ICD Shock Efficacy using Programmable Pulse Width. Presented at: Heart Rhythm Society; April 24-27, 2025. 
  4. Swerdlow CD , Brewer JE, Kass RM, et al. Application of models of defibrillation to human defibrillation data: implications for optimizing implantable defibrillator capacitance. Circulation. 1997;96(9):2813-22. doi: 10.1161/01.cir .96.9.2813. 
  5. Ellenbogen K, Wilkoff G, Kay G, et al. (2007). Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy (3rd ed.). Elsevier Saunders; 542-547. ISBN-13: 978-1- 4160-2536-8. 
  6. Kawata U , Birgersdotter-Green U . (2018). Ventricular Fibrillation and Defibrillation, Encyclopedia of Cardiovascular Research and Medicine. Elsevier, 674-682. ISBN 9780128051542. doi: 10.1016/B978-0-12-809657-4.99764-3.
  7. Efimov I, Kroll M, Tchou P . (2009). Cardiac Bioelectric Therapy. Springer, 468-472. ISBN 978-0-387-79403-7. 
  8. Kroll M, Lehmann M. (1996). Implantable Cardioverter Defibrillator Therapy. Kluwher Academic Publishers, 68 -69. 
  9. Gold MR, Shorofsky SR. Strength-duration relationship for human transvenous defibrillation. Circulation. 1997;96(10):3517-20. doi: 10.1161/01.cir .96.10.3517.
  10. Kroll MW , Swerdlow CD . Optimizing defibrillation waveforms for ICDs. J Interv Card Electrophysiol. 2007;18(3):247-63. doi: 10.1007/s10840-007-9095-z.
  11. Doshi SK, Pittaro MD , Reeves R, et al. Efficacy of tuned waveforms based on different membrane time constants on defibrillation thresholds: primary results from the POWER trial. Pacing Clin Electrophysiol. 2012;35(10):1253-61. doi: 10.1111/j. 1540-8159.2012.03500.x.
  12. Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71-75. doi: 10.1159/000345776. 
  13. Veltmann C, Wöhrle , Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. Presented at: Europace; 2017. 
  14. Piorkowski C, et al. Early real-world adoption of mobile remote monitoring using the Confirm Rx Insertable Cardiac Monitor. Poster presented at: Asia Pacific Heart Rhythm Society; 2018. 
  15. Device IFUs: Abbott Tachycardia Devices Help Manual (ARTEN600307504A), Medtronic manuals (Evera‡ XT, Amplia‡, Cobalt‡ XT, and Crome‡), Boston Scientific manuals (NG4 Tachy ICD, NG4 Tachy CRT-D), and Biotronik (Rivacor‡ ICDs and CRT-Ds, Acticor‡ ICDs and CRT-Ds).

™ indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.
Bluetooth® and the Bluetooth® logo are registered trademarks of Bluetooth® SIG, Inc.

© Abbott 2026. All rights reserved. MAT-2676035 v1.0

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline